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Background: Randomized controlled trials (RCTs) are routinely used in systematic reviews and meta-analyses that
help inform healthcare and policy decision making. The proper reporting of RCTs is important because it acts as a
proxy for health care providers and researchers to appraise the quality of the methodology, conduct and analysis of
an RCT. The aims of this study are to analyse the overall quality of reporting in 23 RCTs that were used in a meta-
analysis by assessing 3 key methodological items, and to determine factors associated with high quality of
reporting. It is hypothesized that studies with larger sample sizes, that have funding reported, that are published in
journals with a higher impact factor and that are in journals that have adopted or endorsed the CONSORT
statement will be associated with better overall quality of reporting and reporting of key methodological items.
Methods: We systematically reviewed RCTs used within an anesthesiology related post-operative pain management
meta-analysis. We included all of the 23 RCTs used, all of which were parallel design that addressed the use of
femoral nerve block in improving outcomes after total knee arthroplasty. Data abstraction was done independently
by two reviewers. The two main outcomes were: 1) 15 point overall quality of reporting score (OQRS) based on the
Consolidated Standards for Reporting Trials (CONSORT) and 2) 3 point key methodological item score (KMIS) based
on allocation concealment, blinding and intention-to-treat analysis.
Results: Twenty-three RCTs were included. The median OQRS was 9.0 (Interquartile Range = 3). A multivariable
regression analysis did not show any significant association between OQRS or KMIS and our four predictor
variables hypothesized to improve reporting. The direction and magnitude of our results when compared to
similar studies suggest that the sample size and impact factor are associated with improved key
methodological item reporting.
Conclusions: The quality of reporting of RCTs used within an anesthesia related meta-analysis is poor to moderate.
The information gained from this study should be used by journals to register the urgency for RCTs to be clear
and transparent in reporting to help make literature accessible and comparable.* Correspondence: ThabanL@mcmaster.ca
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Transparent and well designed, conducted and reported
randomised controlled trials (RCTs) are the gold stand-
ard in evaluating healthcare interventions [1]. The qual-
ity of reporting of RCTs in publications is important
because it acts as a proxy for health care providers and
researchers to appraise the quality of the methodology,
conduct and analysis expected of an RCT [2-6]. The
evaluation of the quality of reporting can be compro-
mised when RCTs lack methodological rigour, thus gen-
erating biased results possibly resulting in exaggeration
or shrinking of treatment effects [1,7-14]. Poor conduct
in the quality of reporting of RCTs may allow the intro-
duction of treatments that are less effective than the
studies themselves report [13]. Hence, it is important to
know the quality of RCTs used in meta-analyses in order
to identify the reliability of the evidence that may inform
treatment and care in medicine, including treatment in
the realm of anesthesiology and pain management
[4,7,12,15,16].
Readers and reviewers of published RCTs need
complete, clearly written, and transparent information
on a study’s methodology and findings in order to assess
its quality [1]. Attempts in assessing the quality of
reporting recurrently fail because authors of RCTs neg-
lect to provide comprehensive and clear descriptions of
critical methodological information [1,17-19]. In re-
sponse to inadequate reporting the Consolidated Stan-
dards of Reporting Trials (CONSORT) group created the
CONSORT statement and published its latest revision of
the statement in 2010 [1,6]. The CONSORT 2010 State-
ment includes a 25 item checklist and a flow diagram.
These are recommended items which should be incorpo-
rated into an RCT [1,6]. The statement provides guid-
ance for reporting all RCTs with a focus on individually
randomised, two groups, parallel trials [1].
Following the CONSORT initial statement publication in
1996, there has been improvement in the quality of report-
ing of some RCTs [1,10,20-22]. However, despite improve-
ments noted, there continues to be observational studies
reporting the inadequate quality of reporting of many RCTs
[1,17], including RCTs in specialized journals [1,21,23-25].
There are a few other studies that have investigated the
quality of reporting of RCTs specifically in anesthesia spe-
cialized journals. Many of them have evaluated the quality
of reporting using items similar to items on the CONSORT
2010 checklist [7,26-28]. Some of the specialty journals in
anesthesiology have also adopted or supported the CON-
SORT statement, yet the quality of reporting of parallel-
group RCTs still remains poor [26]. Improvements made in
the quality of reporting in the last decade may indicate a de-
mand on the “quality, consistency and transparency” [26] of
RCT reporting as well as endorsement of the CONSORTstatement by medical journals which publish clinical trials
[1,26]. The quality of reporting of RCTs may be improved
in specialty journals pertaining to anesthesiology by clearly
illustrating methodology. Areas in methodology requiring
attention are allocation concealment (randomization blind-
ing), blinding of data collectors and “discussion of Type II
error in negative trials” [26].
We have two primary aims for this study. The first aim
of this study is to analyse the overall quality of reporting
and reporting of 3 key methodological items of 23 RCTs
used in a meta-analysis that investigated analgesia out-
comes in RCTs comparing femoral nerve block (FNB) with
epidural and patient-controlled analgesia (PCA) after total
knee arthroplasty [29]. Secondly, we aim to determine fac-
tors associated with higher quality of reporting. We
hypothesized that studies with larger sample sizes, that
have funding reported, that are published in journals with
a higher impact factor and that are in journals that have
adopted, endorsed or supported the CONSORT statement
will be associated with better overall quality of reporting
and reporting of the 3 key methodological items. Our
study is unique in that we evaluated the quality of report-
ing of RCTs used within a meta-analysis using 15 items
plus 3 methodologically related items, all of which were
directly from the CONSORT 2010 checklist. It has been
suggested that the quality of studies included in meta-
analyses should be regularly evaluated as studies show that
inadequate quality of trials may distort the results of sys-
tematic reviews and meta-analyses [9]. We consider it im-
portant to do an update on the status of the quality of
reporting of RCTs published within anesthesia specialized
journals as this will contribute more evidence around the
quality of reporting of RCTs used. Much of our study’s
method was modelled upon a previous study assessing the
quality of reporting of RCTs in general endocrinology lit-
erature [3].Methods
Study selection
The 23 RCTs included in this study for quality of report-
ing and key methodological item evaluation came from a
meta-analysis that compared FNB, with and without sci-
atic nerve block, with epidural and PCA after total knee
arthroplasty [29]. This meta-analysis included 23 RCTs
for its own analysis. It was of interest to this study to
know the reporting quality and reporting of key method-
ology items included in this meta-analysis. All 23 RCTs
assessed were parallel-design and addressed the issue of
comparative treatment effectiveness with respect to mor-
phine consumption, incidence of side effects and pain
experiences, which was scored on a pain scale both at
rest and with activity [29].
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An electronic Excel standardized data collection form
was used to extract data from each of the 23 RCTs. One
pair of trained reviewers (VBD and SZ), both of whom
were blinded to each other’s ratings, abstracted data in-
dependently. This form was pilot tested and subse-
quently modified for final revision. Any disagreement
between the reviewers was rectified by consensus and
chance-adjusted inter-rater agreements were calculated.
The rating of overall reporting quality
We defined the overall quality of reporting as the degree
to which the rationale, design, conduct and analysis of
each RCT, evaluated in this study, were reported. In
order to do this, 15 relevant items from the 2010Table 1 Description of overall quality of reporting items
Item
1. Title or Abstract Identification as a randomiz
structured summary of the
Introduction
2. Background Scientific background and e
3. Objectives Specific objectives or hypot
Methods
4. Participants Eligibility criteria for particip
5. Interventions The interventions for each g
allow replication, including
6. Outcomes Completely defined pre-spe
outcome measures, includin
7. Sample Size How sample size was deter
When applicable, explanatio
and stopping guidelines.
8. Randomization: Sequence Generation Method used to generate th
Type of randomisation; deta
(such as blocking and block
9. Randomization: Implementation There is mention of: Who g
sequence, who enrolled par
10. Statistical Methods Statistical methods used to
Methods for additional anal
Results
11. Participants Flow For each group, the numbe
randomly assigned, received
analysed for the primary ou
together with reasons.
12. Recruitment Dates defining the periods
13. Baseline Data A table showing baseline d
14. Outcomes and Estimates For each primary and secon
and the estimated effect siz
For binary outcomes, presen
15. Harms All important harms or unin
Additional Items
16. Ethical Issues The approval of an ethics co
17. Flowchart A flowchart of participants i
(randomization, allocation, f
Please note that the description describing each CONSORT item used are taken dire
parallel group randomised trials” article [1].CONSORT statement were adopted in this quality of
reporting evaluation of RCTs (Table 1). These 15 items
were chosen because of literature indicating that an ab-
sence in their reporting is associated with a higher level
of bias [6]. The CONSORT discussion items were
excluded because of the subjective nature in assessing
them. Three key methodological qualities that are part of
the CONSORT statement were also included in a separ-
ate assessment. An Overall Quality of Reporting Score
(OQRS), with 15 items in total (score out of 15), was
established. Each of the 15 items was scored 1 if it was
reported and 0 if it was not clearly stated or definitely
not stated. Each RCT assessed could have a possible
score between 0 and 15 inclusively. Two additional items
that are considered important to be present in RCTDescription
ed trial in the title and a
trial design, methods, results, and conclusions.
xplanation of rationale.
heses.
ants. Settings and locations where the data were collected
roup with sufficient details to
how and when they were actually administered.
cified primary and secondary
g how and when they were assessed.
mined.
n of any interim analyses
e random allocation sequence
ils of any restriction
size).
enerated the random allocation
ticipants, and who assigned participants to interventions?
compare groups for primary and secondary outcomes.
yses, such as subgroup analyses and adjusted analyses.
rs of participants who were
intended treatment, and were
tcome. For each group, losses and exclusions after randomisation,
of recruitment and follow-up. Why the trial ended or was stopped.
emographic and clinical characteristics for each group.
dary outcome, results for each group,
e and its precision (such as 95% confidence interval).
tation of both absolute and relative effect sizes is recommended.
tended effects in each group
mmittee and obtaining of informed consent from participants are stated
n each stage of the RCT
ollow-up, and analysis for primary outcome) is provided
ctly from the “CONSORT 2010 Statement: updated guidelines for reporting
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were not included in the calculation of the OQRS. This
included a participant flow chart, as indicated by the
CONSORT statement [6], and an ethical item, as it can
improve a clinical study’s review of its methodology and
patient safety [30].
Rating of key methodology items
Appropriate concealment of allocation mechanisms,
blinding, and numbers analysed (intention-to-treat
principle) were assessed separately because they are
highly important in avoiding bias and distortions of the
effect estimates [4,9,26,31-35]. The methodological items
are also underreported in studies with a high overall
reporting quality score hence emphasizing the need to
assess them separately [34,35].
Appropriate concealment of allocation is a process
that assigns patients in an RCT into alternative treat-
ment groups in a way that will prevent the people who
manage the allocation of patients as well as the patients
themselves from foreknowledge of the allocation mech-
anism. This is done in order to avoid selection bias [8].
Obvious and easily manipulated variables such as med-
ical record numbers or birthdays are not adequate for
use in allocation concealment mechanisms. In order to
avoid selection bias, allocation concealment mechanisms
considered appropriate by the Cochrane Handbook are
centralized randomization schemes, numbered, coded
vehicles and sequentially numbered, sealed and opaque
envelopes [5]. Hence, we considered allocation conceal-
ment to be appropriate in this study if centralized
randomization, numbered, coded vehicles, or opaque,
sealed, and sequentially numbered envelopes were
reported [8].
Blinding refers to the process by which study partici-
pants, health care providers, outcome assessors, data
assessors and manuscript writers are kept unaware of the
intervention to which patients are randomized. Blinding
helps to reduce the risk of knowing which intervention
was received and this is critical, as knowledge of the
assigned intervention can affect outcomes and assess-
ments of outcomes [8,36]. Physicians and textbooks vary
in their understanding and definitions of single, double,
and triple blinding thus making the sole use of these
terms in a study ambiguous in describing the blinding
method. Despite this, single, double and triple blinding
are terms commonly and singularly used to report blind-
ing status without the accompaniment of descriptors in-
dicating who was indeed blinded [36-38]. A meta-
analysis indicated that double blinding is associated with
potential bias reduction; double blinded studies reported
a 15% lower treatment effect than non-blinded studies
[4]. Sometimes there are cases where the blinding of
patients and health care providers is not feasible. This isespecially true in instances where there is a comparison
of the effectiveness of a minimally invasive procedure
with a procedure that is more invasive, as with surgery.
In this case, patients or investigators cannot easily be
blinded [38]. In these instances, where blinding is not
feasible, we considered blinding to have been done ap-
propriately if at least one specific group was unambigu-
ously reported as blinded [3]. In RCTs where blinding
did not have any barriers, at least two groups had to be
unambiguously reported as blinded to fulfill this meth-
odological item criteria [3,8,38].
We defined the numbers analyzed based on the
intention-to-treat (ITT) principle. In this study we define
ITT analysis to include all participants randomized into
a trial and its analysis regardless if treatment or the
intervention was administered, if patients satisfied the
entry criteria, if patients withdrew from the study, or if
there were deviations from the protocol [8,39-41].
Though the meaning of ITT has been interpreted differ-
ently by numerous RCTs, the Cochrane Handbook has
compiled evidence indicating that the definition we have
used prevents biased treatment effects and is a pragmatic
way to understand the effects of a clinical intervention
[41,42].
Each of the three above mentioned methodological
items was scored 1 point if the method was appropriately
reported and performed and 0 points if it was inappro-
priate or ambiguous. A combined methodological score
of these three items was calculated for each trial by add-
ing the scores of each item with a possible score ranging
from 0 to 3 inclusively. This score was termed Key
Methodological Item Score (KMIS). An inter-rater agree-
ment was calculated for each of the three included meth-
odological items as done in a previous study [3].
Definition of predictor variables
Sample size was defined as the number of patients ran-
domized in each trial. The journal impact factor refers to
an index number assigned and calculated by Thomson
Reuters to a particular journal catalogued in Thomson
Reuter's Journal Citation Reports that indicates the fre-
quency with which the "average article" in a specific jour-
nal has been cited in a particular year or period [43].
Funding reported was defined as funding mentioned and
provided for the conduct of the study. Journal adoption
of the CONSORT statement at the time of data abstrac-
tion was defined as the article’s journal endorsing, en-
couraging or enforcing the CONSORT statement for
study submissions at the time the article was reviewed
for this study.
Hypotheses
Journal impact factor, sample size and declared funding
have been correlated with better reporting [3,7,25,44-48].
Table 2 Overall Quality of Reporting: Rating using items
from the CONSORT Statement and two additional items
Item All Articles (n = 23)
Count 95% CI*
1. Title or Abstract 0 (0, 8)
2. Background 22 (20, 23)
3. Objectives 23 (15, 23)
4. Participants 6 (2, 10)
5. Interventions 23 (15, 23)
6. Outcomes 9 (5, 14)
7. Sample Size 19 (15, 22)
8. Randomization: Sequence Generation 8 (4, 13)
9. Randomization: Implementation 1 (0, 3)
10. Statistical Methods 17 (13, 21)
11. Participants Flow 12 (7, 17)
12. Recruitment 3 (0, 6)
13. Baseline Data 22 (20, 23)
14. Outcomes and Estimates 11 (6, 16)
15. Harms 18 (14, 22)
a. Ethical Issues 21 (18, 23)
b. Flowchart 2 (0, 5)
CI: Confidence Interval.
*For item that has non-zero event, the 95% CI was approximated by assuming
the number of events followed a Binomial distribution; for item that has zero
event, the 95% CI was approximated by the rule of three [49].
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been associated with improved reporting of RCTs
[6,7,10,11,22]. We hypothesized that studies with larger
sample sizes, that have funding reported, that are pub-
lished in journals with a higher impact factor and that
are in journals that have adopted, endorsed or supported
the CONSORT statement will be associated with better
quality of reporting and reporting of key methodological
items.
Statistical analysis
The statistical analysis was modeled based on the ana-
lysis done in a previous study looking at the quality of
reporting of general endocrinology literature [3]. The
predictor variables, journal impact factor and sample size
were also assessed in this study [3]. The new predictor
variable included for our study is journal adoption, en-
dorsement or support of the CONSORT statement at the
time of data abstraction and funding reported.
Categorical data were reported as the number of
counts. The number of trials that clearly stated the elem-
ent and the associated 95% confidence interval (CI) were
calculated. For the element that had “zero” count or
“full” counts (i.e. when none of or all of the included
trials reported that element respectively), the 95% CI was
calculated by adopting the rule of three [49]. If none of
the n studies showed the element that we were interested
in, we could be 95% confident that the chance of this
event occurring is at most 3 in n [49]. For the other ele-
ments, the 95% CI of the count was calculated by assum-
ing that the number of trials that clearly stated the
element followed a binomial distribution. The probability
that a trial had clearly stated the element was set to be
the observed probability in the sample. The Cohen’s
Kappa (κ) statistics were used to calculate the chance-
adjusted agreement between the two raters for the 15
quality of reporting items, the 2 additional items (ethical
issues and flow chart) and the 3 key methodological
items. Agreement was interpreted as poor if κ ≤ 0.2; fair
if 0.21 ≤ κ≤ 0.4; moderate if 0.41 ≤ κ ≤0.6; substantial if
0.61 ≤ κ ≤ 0.8; and good if κ> 0.8 [50].
A multivariable regression analysis with the OQRS as
an outcome variable was conducted to determine if a
higher sample size, a higher impact factor, the presence
of funding reported and the journal adoption, endorse-
ment or support of the CONSORT statement was inde-
pendently associated with a better OQRS. These four
variables were used as predictors. The sample size was
transformed by the logarithm function with base 10 to
improve interpretability. The OQRS (discrete, ranged
from 0–15) was assumed to follow a Poisson distribu-
tion. Incidence rate ratios (IRR) were used to express the
results of the analysis. Variables were considered to be
statistically significant at alpha (α) = 0.05. The sameapproach was followed for regression analysis with the
KMIS as the outcome variable. It is also important to
note that we used Variance Inflation Factors (VIFs) to as-
sess collinearity between predictors and none of the VIFs
were greater than 10 showing no major collinearity
among the variables. SPSS© 19.0.0.0 (IBM Corporation,
2010) was used to perform the statistical analysis.
Results
Rating of quality of reporting
The inter-rater agreement (κ) for the quality of report-
ing items varied from 0.646 to 1, indicating substantial
to perfect agreement. The ratings of items for the
OQRS are shown in Table 2. Some factors that consti-
tute the overall quality of reporting score were con-
sistently well reported. These were items 2, 3, 5, and
13 (Background, Objectives, Intervention and Baseline
Data respectively) and they were properly reported in
over 90% of the studies. The other items were poorly
reported in the majority of the RCTs evaluated. Seven
of the 15 items of the overall quality of reporting
score were correctly reported in fewer than 50% of the
studies. These items were Title and Abstract, Partici-
pants, Outcomes, Randomization: Sequence Gener-
ation, Randomization: Implementation, Recruitment,
and Outcomes and Estimates. The mean OQRS was
8.43 (SD = 1.93), and the median was 9.0 (IQR = 3),
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respectively. Among the additional items considered,
ethical issues were consistently well reported in 21 out
of the 23 studies while a participant flow chart was
provided in only 2 of the RCTs evaluated (Table 2).Rating of key methodological items
The inter-rater agreement (κ) for the quality of key
methodological items was 1 for all items, thus there was
perfect agreement. The number of studies that reported
each key methodological item is provided in Table 3.
Among the 23 RCTs, 7 (30.4%) did not report any of the
three key methodological items and none of the 23 stud-
ies evaluated reported all three methodological items.
The reporting of the key methodological items among
studies with an OQRS above the 75th percentile was also
poor. The average key methodological score of articles
with an OQRS above the 75th percentile was 1. Of the
articles above the 75th percentile for the overall quality
of reporting score only 3 articles describe an appropriate
allocation concealment mechanism, 1 article describes
blinding and 1 article describes intention-to-treat ana-
lysis. Consequently, those studies scoring a higher OQRS
did not guarantee a good report of key methodological
items.
An appropriate method of allocation concealment was
reported in only 8 of the 23 RCTs (34.8%), with opaque,
sealed and sequentially numbered envelopes being the
only method reported by all of these 8 RCTs. Most
reports, 15 of 23 (65.2%) did not give any information
about this key methodological item.
Only 6 of the 23 RCTs (26.1%) were blinded according
to the study definition. Among the 18 studies whereTable 3 Reporting Quality of Key Methodology Items
Criteria De
Allocation of Concealment Allocation was considere
study if one of the follow
were reported; 1) central
numbered, coded vehicle
sealed, and sequentially
Blinding Blinding was considered
least one specific group
as blinded if there was a
issue. In cases where blin
at least two groups must
reported as blinding to q
Numbers Analysed (Intention to treat) Intention to treat was de
all patients randomly ass
regardless of whether th
entry criteria, the treatme
and subsequent with wit
CI: Confidence Interval.
*For item that has non-zero event, the 95% CI was approximated by assuming the n
the 95% CI was approximated by the rule of three [49].blinding of patients was considered feasible, only 4 of
those 18 studies specifically reported at least two blinded
groups. Among the 5 studies where blinding of patients
was considered not feasible, 2 reported blinding of an-
other group. Table 3 shows the number of studies report-
ing key methodological items.Factors associated with reporting quality
Table 4 displays the results of the multivariable ana-
lysis of factors associated with the OQRS. Though the
regression model did not show a significant associ-
ation (p< 0.05) for any of these four predictor vari-
ables (sample size, impact factor, journal adoption of
the CONSORT statement at the time of data collec-
tion and funding reported) the model did show a
trend for funding reported, where the presence of
funding reported in a study showed an observed
26.2% more quality of reporting items present or
higher than studies without funding reported, on
average.
The multivariable analysis of factors associated with
better reporting of KMIS also did not show a significant
association for any of these four predictor variables
(Table 5). Nonetheless the model did show a trend for
funding reported as was shown with the regression for
the overall quality score, where the presence of funding
reported in a study showed an observation of 76.6%
more key methodological items present or higher than
studies without funding reported, on average. In
addition, the model showed a trend for impact factor,
where a 1 unit increment in impact factor showed an ob-
servation of 102.2% more key methodological items
present.scription All Articles (n = 23)
Count 95% CI*
d appropriate in a RCT
ing allocation methods
randomization, 2)
s, and 3) opaque,
numbered envelopes
8 (4, 13)
to have occurred if at
was explicitly reported
blinding feasibility
ding was not an issue,
have been explicitly
ualify as appropriate blinding.
5 (1, 9)
fined as the inclusion of
igned in the analysis,
ey actually satisfied the
nt actually received,
hdrawal or protocol deviations.
9 (5, 14)
umber of events followed a Binomial distribution; for item that has zero event,
Table 4 Regression analysis for the Overall Reporting
Qualitya in 23 RCTs
Predictor variable IRR 95% CI P value
Sample Sizeb 0.791 (0.326, 1.919) 0.605
Impact Factor 0.934 (0.722, 1.208) 0.604
Journal adopted CONSORT Statement
at the time of data collection.
0.938 (0.671, 1.312) 0.708
Funding reported 1.262 (0.837, 1.903) 0.266
CI: Confidence Interval; IRR: Incidence Rate Ratio.
a Maximum Possible Score for the Overall Reporting Quality = 15.
b The sample size variable was log(10) transformed. The value is an expression
of the change in the average of the OQRS due to one unit increase in sample
size in the log scale.
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In this study we assessed the RCT reporting quality of
23 RCTs used within a FNB meta-analysis [29]. Most of
these articles came from anesthesia specialty journals,
except for 3 of the RCTs. All RCTs were related to post-
operative management of analgesia after total knee
arthroplasty. The overall quality of reporting of the RCTs
assessed was poor to moderate, with only 4 of the 15
items being reported in over 90% of the articles. We have
identified several areas where reporting of a particular
item was insufficient in most of the studies assessed.
These areas included: Item 1) Title and Abstract, Item 4)
Participants, Item 6) Outcomes, Item 8) Randomization:
Sequence Generation, Item 9) Randomization: Imple-
mentation, Item 11) Participants Flow, Item 12) Recruit-
ment and Item 14) Outcomes and Estimation. Areas
where items were reported moderately well were: Item 7)
Sample size, Item 10) Statistical Methods and Item 15)
Harms. Also very noteworthy was that the reporting of
the key methodological items was poor with less than
50% of the articles reporting any of the 3 key methodo-
logical items (Table 3). Our results agree with many
studies which have assessed the quality of reporting of
RCTs published in medical and subspecialty journals, in-
cluding studies which have focused on journals specia-
lized in anesthesia [3,17,21,23-29,44-46]. All of these
studies showed there is poor quality of reporting, with
the 3 key methodological items assessed in this studyTable 5 Regression analysis for the Key Methodology
Item Scorea in 23 RCTs
Predictor variable IRR 95% CI P value
Sample Sizeb 2.383 (0.191, 29.665) 0.500
Impact Factor 2.022 (0.742, 5.509) 0.169
Journal adopted CONSORT Statement
at the time of data collection.
0.517 (0.148, 1.803) 0.301
Funding reported 1.766 (0.619, 5.040) 0.288
CI: Confidence Interval; IRR: Incidence Rate Ratio.
a Maximum Possible Score for the Key Methodology Item= 3.
b The sample size variable was log(10) transformed. The value is an expression
of the change in the average of the KMIS due to one unit increase in sample
size in the log scale.(appropriate allocation concealment mechanism, blind-
ing and numbers analysed by ITT) being highlighted as
poorly reported [17,21,23-27,35,44]. Even though there is
evidence to suggest that the quality of reporting has sig-
nificantly improved over time, especially with the onset,
use and publication of the CONSORT statement, the
poor quality of reporting overall suggests that the statis-
tically significant improvements are not enough to be
clinically important as higher quality of reporting is
needed to reduce bias and properly support clinicians’
decisions about treatment management [13,20,22,35].
Also, the overall quality of reporting does not necessarily
correspond with the proper reporting of the 3 key meth-
odological items assessed for in this study; 3 items which
are deemed important in preventing bias [9,35]. Alloca-
tion concealment is important in avoiding selection bias,
proper blinding is important in avoiding performance
and detection bias, and numbers analyzed (ITT
principle) is important in avoiding attrition bias [9]. Any
method of randomization, allocation concealment or
blinding which allows the investigator to control the
treatment group to which the study participant will be
assigned should be avoided [27]. Recent studies suggest
that deficiency and poor quality of reporting of these 3
key methodological items often causes bias in the esti-
mate of treatment effects, though the extent of bias can
be unpredictable [27,31,32]. The overall poor quality of
reporting in anesthesia literature is important to high-
light as it suggests that there is a need to standardize the
reporting of RCTs in anesthesia publications where infor-
mation is retrieved, disseminated, and used for clinical
practice. Although the CONSORT group was created to
help improve reporting, there seems to be a need to
register the urgency for completeness, clarity and trans-
parency of reporting [1] in order to make publications
more accessible and easily comparable with one another.
This is apparent with the 23 RCTs assessed for this study
as well since all of these articles were published after the
CONSORT statement was established in 1996. The
introduction of the CONSORT among journals and en-
forcing its use by requiring authors to submit a CON-
SORT checklist has the potential to greatly improve the
quality of reporting for its readers and researchers need-
ing to use the important information that RCTs provide
for future application and meta-analysis. This notion is
supported by evidence shown in 3 recent observational
studies demonstrating that the introduction of the CON-
SORT statement is associated with an improvement in
the quality of reporting [20,22,51].
Limitations
There are many limitations to this study. One of the key
limitations is the small sample size of RCTs used to
evaluate the quality of reporting and key methodological
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evaluate the reporting quality of RCTs used in an actual
meta-analysis. In hindsight, our study may not have had
enough power to detect any significant association with
our four predictor variables. In order to compensate for
this we looked at trends among our findings with two
other studies [3,25] that looked at analogous predictor
variables using comparable methods of statistical ana-
lysis, and their association with the overall quality of
reporting or reporting of key methodological items in
RCTs. We found that two of the predictor variables we
looked at (Sample Size and Impact Factor) had shown a
significant association with reporting quality in these two
studies. We were not able to compare our other two pre-
dictor variables (Journal adoption of CONSORT state-
ment at the time of data collection and funding
reported) with these two comparator studies and with
other studies that were reviewed because of one of three
reasons: 1) the variable was not used as a predictor vari-
able, 2) the findings were not reported in a numerical
and statistical manner that could be used for trend com-
parison, or 3) it was not reported at all in publication.
For the OQRS there were a few noted trends. Though
the direction and the magnitude of the effect of sample
size was not seen as similar to the two comparator stud-
ies, our 95% CI range for sample size encompassed the
IRR of both comparator studies suggesting that there is a
possibility that our results would have showed associ-
ation had the sample size been larger. However, for the
predictor variable of impact factor, which was measured
in our study on a continuous scale, there were no trends
observed in the one study we could use as a comparison.
It should be noted that the comparator paper we could
use for impact factor measured impact factor association
in a categorical manner. Most of the impact factors of
the RCT journals in our study fell into only one of those
categories suggesting that our CI range may have encom-
passed their model had we been able to compare on a
continuous scale. We also had 4 RCTs that came from
journals with no impact factor evaluation for 2010. This
decreased our RCT sample size from 23 to 19, further re-
ducing our power to detect a difference.
For the KMIS there were also a few noted trends with
one of the comparator studies. Both the sample size and
impact factor of our results matched the direction and
range found in the study by Lai et al. suggesting that our
results would have reached significance had the sample
size been larger. This trend is also more likely to be ap-
parent with KMIS, even with the sample size we had, be-
cause of noted studies suggesting that key
methodological items, such as the three used in this
study, are associated with improved quality of reporting
[3,7,25,44-46] and the importance the 3 key methodo-
logical items assessed (Blinding, Allocation Concealmentand Numbers Analysed) have in reducing bias
[6,31,32,36,52]. In the future it might be of interest to as-
sess the quality of RCTs from more than one meta-
analysis on a related topic or even a random sample of
RCTs in recent years in primary journals. Another limi-
tation of our study is the fact that we cannot verify the
degree with which the quality of reporting reflects the
true methodological quality of the RCTs we assessed.
The lack of reporting of a particular item in an RCT
does not mean that the study in truth had a poor meth-
odology. It is possible that the protocols of many RCTs
include important aspects of methodology however im-
portant methodological details were left out of the pub-
lished report [53,54]. In one study it was reported that
the proportion of double blinded trials with a clear de-
scription of the blinding of participants increased from
19%, with reliance on the publication alone, to 67% when
the protocol for the RCT was reviewed and supplemen-
ted for assessment with the publication [55]. Although
the reporting on the key methodological item of blinding
was found to be inadequate in both trial protocols and
publications, the results show that there is still a possibil-
ity that the methodological and reporting quality of an
RCT is greater than what is assessed in the published re-
port [55,56]. Soares et al. also showed that adequate con-
cealment of allocation was achieved in all protocols but
was only reported in 42% of the published papers [56].
Reviewing protocols may improve the quality of report-
ing assessment however the published report is an im-
portant proxy in determining the validity and clinically
relevant effect estimate as it is the source most accessible
to clinicians and researchers. The quality of the report it-
self is important for this purpose. An additional limita-
tion was the fact there is no standard instrument to
evaluate the quality of reporting of RCTs. The majority
of scales have not been thoroughly developed or tested
for in regards to validity and reliability as a gold standard
(criterion validity) is needed to compare it against. A
gold standard does not exist for assessing the quality of
RCTs and so checklists demarcating important features
of quality and scales based on a quality of reporting
checklist are assessed based on face validity and content
validity from a theoretical model founded on accepted
criteria [57,58]. Quality scores based on checklists are
also unreliable and may introduce bias as scores were
found to differ depending on the scoring system that was
used [59,60]. Our results may also not entirely represent
the quality of reporting of RCTs used in meta-analyses
related to the intervention of the meta-analysis we used
[29]. Therefore the assessment of the quality of reporting
of the RCTs used in other anesthesia related meta-
analyses may help in compiling a sufficient pool of stud-
ies providing a sample size with enough power to detect
a significant difference. Even with our limitations our
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fied reviewers and good inter-rater correlation despite
that there was a lack of clarity with the reporting of eval-
uated items. In the future, one important item to add to
the OQRS is trial registration. Trial registration is an-
other recently enforced part of any published RCT article
in order to ensure accessibility of all research. Studies
have shown that the presence of registration with a trial
registry is suboptimal [61,62] and trial registration is
associated with improved reporting in RCTs within the
highest ranked journals [62]. It is also important to note
that the year of publication definitely plays a role in the
reporting quality of the RCTs chosen for our study. The
CONSORT statement was established in 1996 and the
speed of implementation of the guideline from the CON-
SORT group has been substandard as there continue to
be observational studies concluding inadequate quality of
reporting of many RCTs dated from 1996 till now
[1,17,21,23-25]. Indeed, it has been shown that the total
quality of reporting score is significantly associated with
factors such as trial size, publication year, and the impact
factor which the RCT is published within [44,47,48].
With that said the medical research community should
also take notice that impact factor has been shown to be
statistically significant as a predictor for better reporting
quality on several occasions [25,47,48] and may be a fea-
ture to look for when wanting to find RCT publications
that are of high reporting quality. It is possible that a
large proportion of journals that have a higher impact
factor have made initiatives to have authors submitting
RCT manuscripts to their journal to adhere to the CON-
SORT statement. This may be worth investigating in the
future to see if such a relationship exists.Conclusions
In conclusion our study showed that the quality of
reporting and reporting of key methodological items
within anesthesia RCTs used for a post-operative pain
management meta-analysis is poor to moderate. The
knowledge gained from this study should be taken as an-
other opportunity for journals to register the urgency for
RCT publications to be complete, clear and transparent
in reporting in order to make the literature accessible
and comparable. Enforcing the use of the CONSORT
statement by requiring authors to submit a CONSORT
checklist can help greatly to improve the quality of
reporting and get authors in the frame of reference
needed to properly report studies or even structure study
design.Abbreviations
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